# Octagon Capital Advisors

> Octagon Capital Advisors is a VC fund backing Biotechnology and Health Care. See 64 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 64
- Last investment: Aug 2026
- Lead investor: 6%
- Last updated: Aug 2026
- Website: https://octagoninvestments.com/

Octagon Capital Advisors is a VC fund in New York focused on Biotechnology and Health Care. Octagon Capital invests in public and private healthcare companies globally. Octagon Capital focuses on strategic long-term investments and strive to work with our portfolio management teams as partners.

## Contacts

5 contacts available for Octagon Capital Advisors. Shizune tracks 1 team members at Octagon Capital Advisors. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/octagon-capital-advisors?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 44 | 69% |
| Health Care | 32 | 50% |
| Therapeutics | 19 | 30% |
| Medical | 14 | 22% |
| Biopharma | 12 | 19% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 17 | 27% |
| Series B | 16 | 25% |
| Series C | 14 | 22% |
| Series A | 5 | 8% |
| Series E | 3 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 30 | 47% |
| China | 19 | 30% |
| France | 1 | 2% |
| Singapore | 1 | 2% |
| Switzerland | 1 | 2% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ting Jia | Founder and Chief Investment Officer | 5 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Obsidian Therapeutics | Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with newfunctions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies. | $350M | Post-IPO Equity | Aug 04, 2026 |  |
| Processa Pharmaceuticals | Processa Pharmaceuticals operates as a pharmaceutical company. The company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. | $200M | Post-IPO Equity | Jul 29, 2026 |  |
| Adlai Nortye | Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $150M | Post-IPO Equity | Apr 16, 2026 |  |
| Precision BioSciences | Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS.Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editingtechnology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome. | $75M | Post-IPO Equity | Nov 10, 2025 |  |
| Palisade Bio | Palisade Bio is a clinical-stage biopharmaceutical company developing treatments for diseases of unmet medical need. They base these treatments on sound science and therapies with a decades-long history of safe and effective usage. The company's mission is to develop and commercialize novel therapeutics that target diseases resulting from aloss of gastrointestinal barrier integrity. The company was founded in 2011 and is headquartered in Carlsbad, California. | $138M | Post-IPO Equity | Oct 01, 2025 |  |
| BBOT | BridgeBio Oncology Therapeutics operates as a biopharmaceutical company. | $261M | Post-IPO Equity | Aug 11, 2025 |  |
| Verastem Oncology | Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth. | $75M | Post-IPO Equity | Apr 25, 2025 |  |
| DBV Technologies | DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapythat aims to activate the immune system of patients through the skin. | $180M | Post-IPO Equity | Mar 27, 2025 |  |
| Numab | Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics. | $54.8M | Series C | Jan 09, 2025 |  |
| Bluejay Therapeutics | Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients. | $182M | Series C | May 09, 2024 |  |

10 of 64 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 16 deals together
- Octagon Capital Partners — VC Fund, 13 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 12 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 11 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 10 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 9 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Octagon Capital Advisors invest in?

Octagon Capital Advisors invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 64 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Octagon Capital Advisors?

Public channels for Octagon Capital Advisors include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Octagon Capital Advisors?

The team at Octagon Capital Advisors includes Ting Jia (Founder and Chief Investment Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co